ETC
ITCI

Exchange Traded Concepts’s Intra-Cellular Therapies Inc. ITCI Stock Holding History

Exchange Traded Concepts’s Portfolio ITCI Stock Details ITCI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-93
Closed -$6.37K – 1452
2024
Q2 		$6.37K Buy
93
+38
+69% +$2.64K ﹤0.01% 1154
2024
Q1 		$3.81K Buy
+55
New +$3.78K ﹤0.01% 1210
2023
Q1 		– Sell
-2,687
Closed -$142K – 1303
2022
Q4 		$142K Buy
2,687
+339
+14% +$17K ﹤0.01% 733
2022
Q3 		$109K Buy
2,348
+1,049
+81% +$54.8K ﹤0.01% 739
2022
Q2 		$74K Buy
1,299
+754
+138% +$42.8K ﹤0.01% 844
2022
Q1 		$33K Buy
+545
New +$28.3K ﹤0.01% 974

Other funds holding ITCI

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Exchange Traded Concepts's ITCI Position: Q3 2024 in Review

Exchange Traded Concepts sold out of Intra-Cellular Therapies Inc. (ITCI) in Q3 2024, closing a stake of 93 shares — an estimated $6.37K sold.

Exchange Traded Concepts first reported a position in ITCI in Q1 2022 and held it in 6 quarters. The position peaked at $142K in Q4 2022. 355 funds tracked by Wall St. Rank hold ITCI as of Q3 2024.

  • Exchange Traded Concepts reported no remaining Intra-Cellular Therapies Inc. position as of Q3 2024 after selling out during the quarter.
  • Exchange Traded Concepts sold 93 Intra-Cellular Therapies Inc. shares in Q3 2024, an estimated $6.37K.
  • Exchange Traded Concepts first reported a position in Intra-Cellular Therapies Inc. in Q1 2022 and held it in 6 quarters.
  • Exchange Traded Concepts's Intra-Cellular Therapies Inc. position peaked at $142K in Q4 2022.
  • 355 funds tracked by Wall St. Rank held Intra-Cellular Therapies Inc. as of Q3 2024.

Based on Exchange Traded Concepts's 13F filing for Q3 2024, filed 10 Oct 2024.